LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
University of Illinois at Chicago · with Eli Lilly and Company · NCT07408531
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 2500
- US sites recruiting
- 2
- Study start
- March 12, 2026
- Record last updated
- August 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.
Being studied: Sybil Artificial Intelligence (AI) screening
Conditions: Lung Cancer Screening
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 50-80 years at the time of consent
- Meets at least one of the following LCS eligibility criteria:
- USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago.
- Potter: 20 years of smoking, regardless of intensity
- ACS: ≥20 pack-years, no restriction on quit time
- Receiving or scheduled for LDCT through the UI Health Lung Screening Program.
- Willing to view a short (approximately 2-minute) educational video that explains Sybil AI scoring and LCS, complete the Sybil AI survey (if selected), and/or provide blood samples (optional).
- Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC IRB ICF and HIPAA authorization.
- Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
- As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study
Exclusion Criteria
- Inability to undergo LDCT
- Current diagnosis or history of lung cancer \< 5 years prior to study enrollment.
- Life expectancy \<1 year
- Active lung infection requiring systemic therapy
- Vulnerable population, including prisoners and pregnant or nursing women, will not be enrolled due to radiation exposure from LDCT, which is contraindicated in pregnancy.
- Other major comorbidity, as determined by the study PI
- Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.
Recruiting US locations
UI Health
Chicago, IL 60612
Site contact: Mary Pasquinelli, DNP · 312-996-8039 · Mpasqu3@uic.edu
UI Health 55th and Pulaski Health Collaborative
Chicago, IL 60629
Site contact: Mary Pasquinelli, DNP · 312-996-8039 · Mpasqu3@uic.edu
Study contacts (from the official record)
- Mary Pasquinelli, DNP · (312) 996-8039 · Mpasqu3@uic.edu
Similar studies in Illinois
All healthy volunteers studies in Illinois →- RecruitingHealthy volunteers
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
University of Chicago
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Melrose Park, IL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
- Location
- Grayslake, IL + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
AbbVie
- Location
- Grayslake, IL
- Eligibility basics
- Ages 18–65